Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models

Pharmaceutical Statistics - Tập 12 Số 6 - Trang 337-347 - 2013
Bohdana Ratitch1, Michael O’Kelly2, Robert Tosiello3
1Quintiles, Montreal, Quebec, Canada.
2Quintiles, Dublin, Ireland.
3Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

Tóm tắt

The need to use rigorous, transparent, clearly interpretable, and scientifically justified methodology for preventing and dealing with missing data in clinical trials has been a focus of much attention from regulators, practitioners, and academicians over the past years. New guidelines and recommendations emphasize the importance of minimizing the amount of missing data and carefully selecting primary analysis methods on the basis of assumptions regarding the missingness mechanism suitable for the study at hand, as well as the need to stress‐test the results of the primary analysis under different sets of assumptions through a range of sensitivity analyses. Some methods that could be effectively used for dealing with missing data have not yet gained widespread usage, partly because of their underlying complexity and partly because of lack of relatively easy approaches to their implementation. In this paper, we explore several strategies for missing data on the basis of pattern mixture models that embody clear and realistic clinical assumptions. Pattern mixture models provide a statistically reasonable yet transparent framework for translating clinical assumptions into statistical analyses. Implementation details for some specific strategies are provided in an Appendix (available online as Supporting Information), whereas the general principles of the approach discussed in this paper can be used to implement various other analyses with different sets of assumptions regarding missing data. Copyright © 2013 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

European Medicines Agency, 2010, Guideline on missing data in confirmatory clinical trials

National Research Council, 2010, The prevention and treatment of missing data in clinical trials

10.1002/9781119013563

CarpenterJR KenwardMG.Missing data in randomised controlled trials – a practical guide 2007. Available athttp://missingdata.lshtm.ac.uk/downloads/rm04_jh17_mk.pdf(accessed 23 January 2012).

10.2307/2532847

Carpenter J, Analysis of longitudinal trials with protocol deviation:‐ a framework for relevant, accessible assumptions and inference via multiple imputation, Journal of Biopharmaceutical Statistics,

10.1002/9780470316696

10.1002/9780470510445

10.1080/01621459.1993.10594302

10.1201/9781420011579.ch18

10.1093/biostatistics/3.2.245

10.1080/01621459.1996.10476908

10.1080/01621459.1993.10476366

10.1201/9781439821862

10.1002/sim.4067

10.1177/0962280206074463

10.1214/ss/1177010269

10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R

10.1097/01.MLR.0000062554.74615.4C

10.1080/10543400903243009

RatitchB O'KellyM.Implementation of pattern‐mixture models using standard SAS/STAT procedures PharmaSUG2011). Available athttp://pharmasug.org/proceedings/2011/SP/PharmaSUG‐2011‐SP04.pdf(accessed 24 August 2012).

10.1016/j.jpain.2011.06.003

Mallinckrodt C, 2011, Hypotheses, Endpoints, and Analyses for Incomplete Longitudinal Clinical Trial Data

Thông tin
Thông tin xuất bản

Pharmaceutical Statistics

Tập 12 Số 6

337-347

Thông tin tác giả